HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vellas, B. Search for Related Content PubMed PubMed Citation Articles by Vellas, B.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

The GuidAge study

Methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761® for prevention of Alzheimer disease in patients over 70 with a memory complaint

INSERM (French National Institute of Health and Medical Research), U558, F-31073 Toulouse, France; University Toulouse III, Toulouse, France (Dr. Vellas, Dr. Andrieu, Dr. Ousset); CHU Toulouse, Hôpital Casselardit, Service of internal medicine and clinical gerontology, Toulouse, France (Dr. Vellas, Dr. Ousset); CHU Toulouse, Service of epidemiology and public health, Toulouse, F-31073 France (Dr. Andrieu); IPSEN, Paris, France (Dr. Ouzid, Dr. Mathiex-Fortunet).

Address correspondence to: Pr B Vellas, Hôpital Casselardit, Service de médecine interne et gérontologie clinique, 170 avenue de Casselardit, 3100 Toulouse, France, email: vellas.b{at}chu-toulouse.fr

Background: Preventive approaches in the field of Alzheimer disease (AD) is important but these trials raise many questions. Which protective factor should be studied? What population should be studied? With which principal and secondary criteria? We present here the design of the ongoing GuidAge Study. In the past, several studies suggest that Ginkgo biloba could have a potential benefit effect on cognitive function. The aim of the GuidAge Study is to evaluate the efficacy of 240 mg/d of EGb 761® in the prevention of AD.

Methods: GuidAge is a 5-year double-blind randomized trial conducted in France by a private practice/hospital network of general practitioners and hospital practitioners specializing in memory disorders. This study enrolled elderly subjects with spontaneous memory complaint and the primary outcome is the incidence of AD during a 5 years follow-up period. A total of 2854 subjects were enrolled between March 2002 and September 2004. The age of the study population was 76.8 ± 4.4 with mean MMSE at entry 27.8 ± 1.7.

Conclusion: The GuidAge study is the largest study carried out in Europe on the prevention of AD. Final results should be available in 2010.

*See the Appendix for a list of GuidAge Study Group members

Publication of this supplement was supported by an educational grant from Beaufour Ipsen.

Disclosure: The sponsor has provided B.V. with an honorarium for his participation in this project, honorarium during his career, and grant support.

This article has been cited by other articles:

				J. Kaye Ginkgo biloba Prevention Trials: More Than an Ounce of Prevention Learned Arch Neurol, May 1, 2009; 66(5): 652 - 654. [Full Text] [PDF]

				S. T. DeKosky, J. D. Williamson, A. L. Fitzpatrick, R. A. Kronmal, D. G. Ives, J. A. Saxton, O. L. Lopez, G. Burke, M. C. Carlson, L. P. Fried, et al. Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial JAMA, November 19, 2008; 300(19): 2253 - 2262. [Abstract] [Full Text] [PDF]

				N. Coley, S. Andrieu, V. Gardette, S. Gillette-Guyonnet, C. Sanz, B. Vellas, and A. Grand Dementia Prevention: Methodological Explanations for Inconsistent Results Epidemiol. Rev., November 1, 2008; 30(1): 35 - 66. [Abstract] [Full Text] [PDF]

				H. H. Dodge, T. Zitzelberger, B. S. Oken, D. Howieson, and J. Kaye A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline Neurology, May 6, 2008; 70(19_Part_2): 1809 - 1817. [Abstract] [Full Text] [PDF]